

## APPENDIX A: Mark-up of amended claims

1. (Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X<sub>1</sub>-His-Lys-X-Lys-X<sub>2</sub> wherein

X is any amino acid,

X<sub>1</sub> is [from zero to twelve amino acids] the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or an N-terminal truncation fragment thereof containing at least one amino acid, and

X<sub>2</sub> is [from zero to twelve amino acids,]

(i) zero amino acids, or

(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or a C-terminal truncation fragment thereof containing at least one amino acid,

and wherein said compound optionally comprises an amino-terminal protecting group [and/or] and optionally comprises a carboxy-terminal protecting group.

16. (Amended) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a [composition according to claim 1] pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X<sub>1</sub>-His-Lys-X-Lys-X<sub>2</sub> wherein

X is any amino acid,

X<sub>1</sub> is from zero to twelve amino acids, and

X<sub>2</sub> is from zero to twelve amino acids,

and wherein said compound optionally comprises an amino-terminal protecting and optionally comprises a carboxy-terminal protecting group.

30. (amended) A compound of the formula X<sub>1</sub>-His-Lys-X-Lys-X<sub>2</sub> wherein

X<sub>1</sub> is

the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or N-terminal truncation fragment thereof containing at least one amino acid, and

X<sub>2</sub> is

(i) zero amino acids, or

(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or C-terminal truncation fragment thereof containing at least one amino acid,

and wherein said compound optionally comprises an amino-terminal protecting group [and/or] and optionally comprises a carboxy-terminal protecting group.

32. (amended) The compound of claim 30 having [substantial] at least about 30% amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-His-Val (SEQ ID NO:5).

## APPENDIX B: Mark-up of specification paragraphs amended

Page 10, lines 6-9:

(amended) Fig. 2 shows the concentration-dependent inhibition of endothelial cell proliferation by HK<sub>a</sub> ([black] fine crosshatched bars), HK (white bars) and low molecular weight kininogen ([stippled] course crosshatched bars). Low molecular weight kininogen is non-inhibitory.

Page 10, lines 15-19:

(amended) Fig. 5 shows the inhibition of endothelial cell proliferation as a function of HK<sub>a</sub> concentration and cell density in the culture. White bars = 1,500 cells/well; [diagonally hatched] course crosshatched bars = 3,000 cells/well; [grey] fine crosshatched bars = 6,000 cells/well; [black] very fine crosshatched bars = 12,000 cells/well; vertically hatched bars = 24,000 cells/well.

Page 20, lines 21:

(amended) % inhibition =  $(1 - [(A_{490} (+GF, HK_a) - A_{490} (-GF)) / (A_{490} (-GF) \cdot A_{490} (+GF)) - A_{490} (-GF)])] \times 100,$